Submit your email to push it up the queue
Kitasato Daiichi Sankyo Vaccine Co., Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Japan. Established in 2005, the company has rapidly evolved, focusing on the research, development, and production of innovative vaccines. With a strong operational presence in Asia and beyond, Kitasato Daiichi Sankyo is dedicated to addressing global health challenges through its advanced vaccine solutions. The company’s core offerings include a range of vaccines designed to combat infectious diseases, distinguished by their cutting-edge technology and rigorous safety standards. Kitasato Daiichi Sankyo has achieved notable milestones, including collaborations with international health organisations, positioning itself as a trusted name in vaccine development. With a commitment to quality and innovation, the company continues to play a vital role in enhancing public health worldwide.
How does Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s score of 74 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kitasato Daiichi Sankyo Vaccine Co., Ltd., headquartered in Japan, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives. While Kitasato Daiichi Sankyo Vaccine Co., Ltd. has not set specific reduction targets or disclosed its own climate pledges, it inherits sustainability initiatives from its parent company, Daiichi Sankyo Company, Limited. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which aim to enhance corporate accountability in reducing carbon emissions and transitioning to renewable energy sources. As a subsidiary, Kitasato Daiichi Sankyo Vaccine Co., Ltd. aligns with the broader climate strategies of Daiichi Sankyo Company, Limited, which are designed to mitigate environmental impact and promote sustainability within the pharmaceutical and vaccine sectors.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 182,519,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 290,715,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 5,704,000 | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kitasato Daiichi Sankyo Vaccine Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.